Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 10, 2021
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
[ Thu, Jun 10th 2021
] - WOPRAI
Michael King Initiated (AGIO) at Strong Buy and Held Target at $88 on, Jun 10th, 2021
Michael King of HC Wainwright & Co., Initiated "Agios Pharmaceuticals, Inc." (AGIO) at Strong Buy and Held Target at $88 on, Jun 10th, 2021.
Michael has made no other calls on AGIO in the last 4 months.
There are 3 other peers that have a rating on AGIO. Out of the 3 peers that are also analyzing AGIO, 2 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Downgraded from Buy to Hold and Held Target at $54 on, Monday, March 1st, 2021
- Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $50 on, Friday, February 26th, 2021
This is the rating of the analyst that currently disagrees with Michael
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $65 on, Friday, April 30th, 2021
